News | August 16, 2022
Marksans Pharma posts Q1FY23consolidated PAT at Rs. 59.71 Cr
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Company appoints five new independent directors to reconstituted board
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Man lost 54 Kgs in 6 months with MGB procedure
Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation
Subscribe To Our Newsletter & Stay Updated
